Skip to main content
OTCMKTS:MMEDF

Mind Medicine (MindMed) Competitors

$3.23
+0.24 (+8.03 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.06
$3.33
50-Day Range
$2.13
$4.69
52-Week Range
$0.29
$5.07
Volume6.50 million shs
Average Volume3.38 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Mind Medicine (MindMed) (OTCMKTS:MMEDF) Vs. DDXS, TNGN, ATTBF, ADTX, AGNPF, and LBTSF

Should you be buying MMEDF stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Mind Medicine (MindMed), including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), ADiTx Therapeutics (ADTX), Algernon Pharmaceuticals (AGNPF), and Almirall (LBTSF).

Mind Medicine (MindMed) (OTCMKTS:MMEDF) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and (DDXS)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/AN/AN/AN/A
(DDXS)N/AN/AN/AN/AN/A

Profitability

This table compares Mind Medicine (MindMed) and (DDXS)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mind Medicine (MindMed)N/AN/AN/A
(DDXS)N/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Mind Medicine (MindMed) and (DDXS), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mind Medicine (MindMed)00103.00
(DDXS)0000N/A

Mind Medicine (MindMed) currently has a consensus target price of $2.00, indicating a potential downside of 38.08%. Given Mind Medicine (MindMed)'s higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than (DDXS).

Summary

Mind Medicine (MindMed) beats (DDXS) on 2 of the 2 factors compared between the two stocks.

Mind Medicine (MindMed) (OTCMKTS:MMEDF) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and (TNGN)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/AN/AN/AN/A
(TNGN)N/AN/AN/AN/AN/A

Profitability

This table compares Mind Medicine (MindMed) and (TNGN)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mind Medicine (MindMed)N/AN/AN/A
(TNGN)N/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Mind Medicine (MindMed) and (TNGN), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mind Medicine (MindMed)00103.00
(TNGN)0000N/A

Mind Medicine (MindMed) currently has a consensus target price of $2.00, indicating a potential downside of 38.08%.

Summary

Mind Medicine (MindMed) beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Mind Medicine (MindMed) (OTCMKTS:MMEDF) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and Abattis Bioceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/AN/AN/AN/A
Abattis BioceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Mind Medicine (MindMed) and Abattis Bioceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mind Medicine (MindMed)N/AN/AN/A
Abattis BioceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Mind Medicine (MindMed) and Abattis Bioceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mind Medicine (MindMed)00103.00
Abattis Bioceuticals0000N/A

Mind Medicine (MindMed) currently has a consensus target price of $2.00, indicating a potential downside of 38.08%. Given Mind Medicine (MindMed)'s higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Abattis Bioceuticals.

Summary

Mind Medicine (MindMed) beats Abattis Bioceuticals on 2 of the 2 factors compared between the two stocks.

Mind Medicine (MindMed) (OTCMKTS:MMEDF) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and ADiTx Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/AN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Mind Medicine (MindMed) and ADiTx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mind Medicine (MindMed)N/AN/AN/A
ADiTx TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Mind Medicine (MindMed) and ADiTx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mind Medicine (MindMed)00103.00
ADiTx Therapeutics00103.00

Mind Medicine (MindMed) currently has a consensus target price of $2.00, indicating a potential downside of 38.08%. Given Mind Medicine (MindMed)'s higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than ADiTx Therapeutics.

Summary

Mind Medicine (MindMed) beats ADiTx Therapeutics on 1 of the 1 factors compared between the two stocks.

Mind Medicine (MindMed) (OTCMKTS:MMEDF) and Algernon Pharmaceuticals (OTCMKTS:AGNPF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Mind Medicine (MindMed) and Algernon Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mind Medicine (MindMed)00103.00
Algernon Pharmaceuticals0000N/A

Mind Medicine (MindMed) currently has a consensus target price of $2.00, indicating a potential downside of 38.08%. Given Mind Medicine (MindMed)'s higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Algernon Pharmaceuticals.

Valuation & Earnings

This table compares Mind Medicine (MindMed) and Algernon Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/AN/AN/AN/A
Algernon PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Mind Medicine (MindMed) and Algernon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mind Medicine (MindMed)N/AN/AN/A
Algernon PharmaceuticalsN/AN/AN/A

Summary

Mind Medicine (MindMed) beats Algernon Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Almirall (OTCMKTS:LBTSF) and Mind Medicine (MindMed) (OTCMKTS:MMEDF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Almirall and Mind Medicine (MindMed), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Almirall01102.50
Mind Medicine (MindMed)00103.00

Mind Medicine (MindMed) has a consensus target price of $2.00, indicating a potential downside of 38.08%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than Almirall.

Earnings and Valuation

This table compares Almirall and Mind Medicine (MindMed)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlmirallN/AN/AN/AN/AN/A
Mind Medicine (MindMed)N/AN/AN/AN/AN/A

Profitability

This table compares Almirall and Mind Medicine (MindMed)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AlmirallN/AN/AN/A
Mind Medicine (MindMed)N/AN/AN/A

Summary

Mind Medicine (MindMed) beats Almirall on 2 of the 2 factors compared between the two stocks.

pixel
Ad IPM
Legendary Crypto Analyst Names 3 Coins to Buy Instead of Coinbase
Matt McCall’s crypto portfolio has delivered multiple 1,000% winners in just months… Now he’s naming 3 tokens he believes folks should own instead of the Coinbase stock in a free report.

Mind Medicine (MindMed) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
(DDXS) logo
DDXS
(DDXS)
0.5$0.00+0.0%$0.00N/A0.00
TNGN
(TNGN)
0.4N/AN/A$0.00N/A0.00Gap Down
Abattis Bioceuticals logo
ATTBF
Abattis Bioceuticals
0.4$0.01+0.0%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.30+1.3%$0.00N/A0.00Earnings Announcement
Algernon Pharmaceuticals logo
AGNPF
Algernon Pharmaceuticals
0.0$0.13+0.0%$0.00N/A0.00News Coverage
Almirall logo
LBTSF
Almirall
0.5$15.15+1.5%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00
ARNI
Arno Therapeutics
0.5$0.01+0.0%$0.00N/A0.00
ASCLF
Ascletis Pharma
0.4$0.00+92,400.0%$0.00N/A0.00Gap Down
AXIM Biotechnologies logo
AXIM
AXIM Biotechnologies
0.4$0.67+10.4%$0.00N/A0.00
BXRXV
Baudax Bio
0.5N/AN/A$0.00N/A0.00High Trading Volume
BerGenBio ASA logo
BRRGF
BerGenBio ASA
0.7$3.52+0.0%$0.00N/A0.00
Cannabics Pharmaceuticals logo
CNBX
Cannabics Pharmaceuticals
0.4$0.19+0.0%$0.00N/A0.00Gap Up
ORHOF
CannaRoyalty
0.7$9.23+56.1%$0.00N/A0.00Gap Up
Cerebain Biotech logo
CBBT
Cerebain Biotech
0.0$0.05+0.0%$0.00N/A0.00
CGYG
China Longyi Group International
0.4$0.00+0.0%$0.00N/A0.00
Claritas Pharmaceuticals logo
KALTF
Claritas Pharmaceuticals
0.6$0.03+0.0%$0.00N/A0.00Gap Down
CLVLY
Clinuvel Pharmaceuticals
1.0$22.65+4.9%$0.00N/A0.00Gap Up
CELZ
Creative Medical Technology
0.5$0.03+0.0%$0.00N/A0.00News Coverage
Gap Down
Eastgate Biotech logo
ETBI
Eastgate Biotech
0.5$0.00+33.3%$0.00N/A0.00News Coverage
Gap Up
EMMBF
Emblem
0.6$1.40+1.4%$0.00N/A0.00
ENZC
Enzolytics
0.0$0.12+16.1%$0.00N/A0.00Gap Down
GB Sciences logo
GBLX
GB Sciences
0.5$0.05+0.0%$0.00N/A0.00News Coverage
Gap Down
Genfit logo
GNFTF
Genfit
0.5$4.17+0.0%$0.00N/A0.00News Coverage
GMXAY
GENMAB A/S/S
0.5$37.08+1.0%$0.00N/A0.00High Trading Volume
Genus logo
GENSF
Genus
0.7$66.00+0.0%$0.00N/A0.00
HALB
Halberd
0.0$0.03+0.0%$0.00N/A0.00News Coverage
Gap Down
HAVN Life Sciences logo
HAVLF
HAVN Life Sciences
0.0$0.63+0.4%$0.00N/A0.00News Coverage
Idorsia logo
IDRSF
Idorsia
0.5$25.00+4.2%$0.00N/A0.00Gap Down
IPATF
ImmunoPrecise Antibodies
0.5N/AN/A$0.00N/A0.00High Trading Volume
IMLFF
InMed Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Innovation Pharmaceuticals logo
IPIX
Innovation Pharmaceuticals
0.6$0.19+0.0%$0.00N/A0.00
Medican Enterprises logo
MDCN
Medican Enterprises
0.5$0.00+0.0%$0.00N/A0.00Gap Up
Mesoblast logo
MEOBF
Mesoblast
0.5$1.34+0.0%$0.00N/A0.00
MCURF
Mind Cure Health
0.0$0.27+0.9%$0.00N/A0.00News Coverage
Gap Down
Molecular Partners logo
MLLCF
Molecular Partners
0.5$22.48+0.4%$0.00N/A0.00
MorphoSys logo
MPSYF
MorphoSys
0.0$93.05+0.0%$0.00N/A0.00
NRNVF
Nordic Nanovector ASA
0.0$1.64+0.0%$0.00N/A0.00High Trading Volume
Novozymes A/S logo
NVZMF
Novozymes A/S
0.4$74.15+5.7%$0.00N/A0.00Gap Up
BPSR
Organicell Regenerative Medicine
0.5$0.22+9.0%$0.00N/A0.00News Coverage
Gap Up
Oxurion logo
TBGNF
Oxurion
0.5$2.94+0.0%$0.00N/A0.00
Pharnext logo
PNEXF
Pharnext
0.0$3.99+0.0%$0.00N/A0.00
PTEO
Proteo
0.5$0.09+0.0%$0.00N/A0.00
PROT
Proteonomix
0.5$0.02+0.0%$0.00N/A0.00
ProtoKinetix logo
PKTX
ProtoKinetix
0.5$0.20+6.6%$0.00N/A0.00Gap Up
PureTech Health logo
PTCHF
PureTech Health
0.0$5.24+0.7%$0.00N/A0.00
RCPHF
Recipharm AB (publ)
1.0$16.05+0.0%$0.00N/A0.00High Trading Volume
Regen BioPharma logo
RGBP
Regen BioPharma
0.0N/AN/A$0.00N/A0.00News Coverage
Relief Therapeutics logo
RLFTF
Relief Therapeutics
0.5$0.22+4.5%$0.00N/A0.00News Coverage
BSSP
Reve Technologies
0.0$0.00+14.3%$0.00N/A0.00Gap Up
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.